Free shipping on all orders over $ 500


Cat. No. M10279
Ibiglustat Structure

Venglustat; SAR402671; GZ402671

Size Price Availability Quantity
5mg USD 210  USD210 In stock
10mg USD 320  USD320 In stock
25mg USD 600  USD600 In stock
50mg USD 960  USD960 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Ibiglustat (Venglustat) can cross the blood-brain barrier. Ibiglustat can prevent additional GL-3 accumulation and could serve to ameliorate the abundant levels of this sphingolipid in FD cardiomyocytes.

Chemical Information
Molecular Weight 389.49
Formula C20H24FN3O2S
CAS Number 1401090-53-6
Solubility (25°C) DMSO ≥ 40 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Iva Stojkovska, et al. Cell Tissue Res. Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease

[2] Jean-Michel Itier, et al. J Inherit Metab Dis. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease

Related Glucosylceramide Synthase Products

G43 is a potent, selective glucosyltransferase inhibitor, with the Kd of 3.7μM and 46.9 nM for GtfB and GtfC, respectively.

Glucosylceramide synthase-IN-1 

Glucosylceramide synthase-IN-1 (T-036) a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 31 nM and 51 nM for human GCS and mouse GCS, respectively. Glucosylceramide synthase-IN-1 can be used for Gaucher's disease research.


D-threo-PDMP is a potent glucoceramide synthase (GCS) inhibitor, which reduces the glycosphingolipids on the cell surface by inhibiting glycosylation, reduces the total length of the axon plexus and the number of axon branch points, and inhibits neurite growth.


Lucerasta is the galactose form of Miglustat, an orally active inhibitor of glucosylceramide synthase (GCS).Lucerastat has potential for use in Fabry disease research.

Glucosylceramide synthase-IN-2

Glucosylceramide-IN-2 (T-690) is a potent, blood-brain barrier-transparent and orally active inhibitor of glucosylceramide synthase (GCS) with IC50s of 15 nM and 190 nM for human GCS and mouse GCS, respectively. basal and non-competitive with UDP-glucose.

Abmole Inhibitor Catalog

Keywords: Ibiglustat, Venglustat; SAR402671; GZ402671 supplier, Glucosylceramide Synthase, inhibitors, activators

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.